Results 81 to 90 of about 8,661 (182)

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir [PDF]

Introduction: We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression. Methods: We
Albertini, Lorenzo, Augello, Matteo, Bai, Francesca, Beringheli, Tomaso, Biasioli, Lorenzo, Bini, Teresa, Bono, Valeria, Castoldi, Roberto, Copes, Alessandro, Gemignani, Nicole, Ligresti, Riccardo, Lundgren, Lorenzo Brando, Marchetti, Giulia, Molà, Francesco, Monforte, Antonella d'Arminio, Nardo, Riccardo, Orfeo, Nicola Vincenzo, Passarella, Sabrina, Pettenuzzo, Sofia, Rovito, Roberta, Sala, Matteo, Santoro, Andrea, Varisco, Benedetta, Vitaletti, Virginia   +23 more
core   +1 more source

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight

Frontiers in Pharmacology
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study,
Giang H. Ta, Max K. Leong
doaj   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses [PDF]

Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that can evade vaccine-elicited ...
Adams, Lily E, Babusis, Darius, Bannister, Roy, Baric, Ralph S, Baric, Thomas J, Barrett, Kimberly T, Bilello, John P, Brown, Ariane J, Catanzaro, Nicholas J, Cihlar, Tomas, Conrad, Helen, De la Cruz, Gabriela, Diefenbacher, Meghan V, Dong, Stephanie, Feng, Joy Y, Gully, Kendra L, Kalla, Rao, Mackman, Richard L, Mallory, Michael L, Martinez, David R, May, Samantha R, Montgomery, Stephanie A, Moreira, Fernando R, Nguyen, Anh-Hoa, Nguyen, Anh-Quan, Nguyen, Cameron, Perry, Jason K, Schäfer, Alexandra, Scobey, D Trevor, Sheahan, Timothy P, Yount, Boyd, Zweigart, Mark R   +31 more
core   +2 more sources

Host‐Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules

Advanced Science, Volume 13, Issue 12, 27 February 2026.
Amid the ongoing threat of emerging viral pathogens, host‐directed antivirals offer a strategy to overcome viral mutation and drug resistance. SB2960, a small‐molecule inducer of stress granules (SGs), exhibits potent broad‐spectrum antiviral activity with minimal cytotoxicity.
Wan Gi Byun, Sumin Son, JinAh Lee, Minha Lee, Meehyun Ko, Songrui Zhao, Ju Hee Kim, Kannan Vaithegi, Ji Hoon Kwon, Jung Ho Lee, Sangeun Jeon, Dawon Yi, Peng Zou, Seungtaek Kim, Seung Bum Park   +14 more
wiley   +1 more source

Nirmatrelvir Plus Ritonavir: First Approval

Drugs, 2022
Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir and ritonavir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19). Nirmatrelvir is a peptidomimetic inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS ...
openaire   +2 more sources

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study

Viruses
This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity, outcomes, and the efficacy of the antiviral agent Paxlovid (nirmatrelvir/ritonavir).
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Oleksandr Kamyshnyi   +3 more
doaj   +1 more source

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj  

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]

Osong Public Health and Research Perspectives
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim   +7 more
doaj   +1 more source

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19. A prospective study [PDF]

COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID19 patients' efficacy, safety, and cost.
Cattaruzza, Maria Sofia, Cipriano, Enrica, Lordi, Margherita, Pietrantonio, Filomena, Rosiello, Francesco, Ruggeri, Matteo, Vinci, Antonio   +6 more
core   +1 more source